BRISTOL MYERS SQUIBB
- Country
- ๐ซ๐ทFrance
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Safety Study of Apixaban in Recent Acute Coronary Syndrome
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2015-12-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1741
- Registration Number
- NCT00313300
- Locations
- ๐บ๐ธ
Midwest Cardiology Research Foundation, Columbus, Ohio, United States
๐บ๐ธGeorgia Heart Specialists, Covington, Georgia, United States
๐บ๐ธHeartcare Midwest, Peoria, Illinois, United States
A Phase IV Study of BMS-232632 in HIV+ Patients With Metabolic Syndrome
- Conditions
- First Posted Date
- 2006-04-11
- Last Posted Date
- 2016-09-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 70
- Registration Number
- NCT00312754
- Locations
- ๐ซ๐ท
Local Institution, Paris, France
Study of BMS-663513 in Patients With Advanced Cancer
- First Posted Date
- 2006-03-31
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 115
- Registration Number
- NCT00309023
- Locations
- ๐บ๐ธ
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
๐บ๐ธCity Of Hope National Medical Center, Duarte, California, United States
๐บ๐ธYale University School Of Medicine, New Haven, Connecticut, United States
Phase I Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris
- Conditions
- First Posted Date
- 2006-03-27
- Last Posted Date
- 2011-04-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 45
- Registration Number
- NCT00306878
- Locations
- ๐บ๐ธ
Local Institution, Pittsburgh, Pennsylvania, United States
Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia
- First Posted Date
- 2006-03-23
- Last Posted Date
- 2021-02-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 63
- Registration Number
- NCT00306202
- Locations
- ๐ฌ๐ง
Local Institution, Birmingham, West Midlands, United Kingdom
Study of BMS-582664 in Combination With Either FOLFIRI or FOLFOX for Gastrointestinal (GI) Malignancies
- Conditions
- First Posted Date
- 2006-03-08
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 50
- Registration Number
- NCT00300027
- Locations
- ๐บ๐ธ
Local Institution, Temple, Texas, United States
A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate
- Conditions
- Interventions
- First Posted Date
- 2006-03-06
- Last Posted Date
- 2010-02-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 400
- Registration Number
- NCT00298987
- Locations
- ๐จ๐ฆ
Local Institution, Montreal, Quebec, Canada
MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma
- Conditions
- First Posted Date
- 2006-03-02
- Last Posted Date
- 2010-04-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 45
- Registration Number
- NCT00298467
- Locations
- ๐บ๐ธ
California Oncology of the Central Valley, Fresno, California, United States
๐บ๐ธMayo Clinic, Rochester, Minnesota, United States
๐บ๐ธCity of Hope, National Medical Center, Duarte, California, United States
A Dose-Escalation Study of MDX-1100 in Patients With Active Ulcerative Colitis
- Conditions
- Interventions
- First Posted Date
- 2006-02-23
- Last Posted Date
- 2010-04-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 24
- Registration Number
- NCT00295282
- Locations
- ๐บ๐ธ
University of Medicine and Dentistry of New Jersery (UMDNJ), New Brunswick, New Jersey, United States
๐บ๐ธCedars-Sinai Medical Center, Los Angeles, California, United States
๐บ๐ธMount Sinai School of Medicine, New York, New York, United States
Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
- Conditions
- Interventions
- First Posted Date
- 2006-02-10
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 210
- Registration Number
- NCT00289640
- Locations
- ๐บ๐ธ
Center For Oncology Research & Treatment, P.A., Dallas, Texas, United States
๐บ๐ธOncology Specialists, Sc, Park Ridge, Illinois, United States
๐บ๐ธSt Joseph Oncology Inc, St Joseph, Missouri, United States